Myriad Genetics (MYGN) stock price, chart and financials

Price chart

Revenue (trailing twelve months)

$806.6M

Revenue (quarter)

$190.7M

Revenue growth (year over year)

−10.51%

Gross profit (trailing twelve months)

$555.2M

Gross margin

68.83%

Net income (trailing twelve months)

−$112.6M

Net income (quarter)

−$43.2M

Net income growth (year over year)

+86.93%

Net margin

−13.96%

Return on equity

−32.54%

EPS (trailing twelve months)

−$1.18

Book value per share

$3.18

P/E (trailing twelve months)

—

Price to book

1.28

Debt to assets

52.43%

Payout ratio

—

Dividend yield

—

Company profile

Myriad Genetics Inc is a molecular diagnostics and precision medicine company committed to advancing health and well-being for all. The company develops and commercializes molecular tests that help patients and providers uncover genetic insights. Its tests assess the risk of developing disease or disease progression and guide treatment decisions across medical specialties, supporting earlier detection, more precise treatment, and lowering healthcare costs. Its tests include BRACAnalysis CDx, EndoPredict, FirstGene, Foresight, GeneSight, MyChoice CDx, MyRisk (cancer treatment), MyRisk (cancer risk), Prequel, Precise Tumor, Prolaris, and SneakPeek. The company operates in the US and Rest of World, with maximum revenue from the US.

• Is Myriad Genetics (MYGN) profitable?

  No. Myriad Genetics reported a net loss of $112.6M over the trailing twelve months.

• How much revenue does Myriad Genetics (MYGN) make?

  Myriad Genetics generated $806.6M in revenue over the trailing twelve months, down 10.51% year over year.

• How do I buy stock in Myriad Genetics (MYGN)?

  MYGN trades commission-free with a Light Horse Securities brokerage account — from the mobile app, the web at Light Horse Dashboard, the trading API, or an AI agent connected over MCP. The trade panel on this page places the order once you are signed in.